BioSpace News Archive

Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global indirect calorimeter market is expected to grow at a moderate pace during the forecast period between 2020 to 2030.

90% of individuals, mainly adolescence. Growing prevalence of skin and soft tissue infections is key to evolution of demand in the topical antibiotic pharmaceuticals market.

Satellos Bioscience Inc., a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced that Frank Gleeson, Founder and CEO, will present live at VirtualInvestorConferences.com on December 16th.

Roche announced the launch of the first infectious disease tests on the cobas® 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the pricing of $300.0 million aggregate principal amount of its Convertible Senior Notes due 2028 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has announced a new safety update on aviptadil, which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the U.S. National Institutes of Health.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria (HCU).

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced preclinical data demonstrating the synergistic anti-leukemic effects of pelareorep combined with the chemotherapeutic agent azacitidine.

MEDX Xelerator is scouting worldwide for disruptive products, ideas and unmet needs in interventional oncology and has commenced its first annual million dollar challenge in this pursuit.